When is allergen immunotherapy effective?

Akane Hara, Yoh Iwasa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Allergen immunotherapy is used to treat allergic symptoms such as rhinitis and itchy eyes in Japanese patients with cedar pollen allergy (JCPA). Administration of small amounts of pollen over several years may suppress severe allergic symptoms when these patients are later exposed to large amounts of pollen in the environment. Herein, we developed a simple mathematical model to identify conditions in which allergen immunotherapy is effective. We considered the dynamics of type 2 T helper cells (Th2) and regulatory T cells (Treg), both of which differentiate from naive T cells. Therapy was considered successful under the following three conditions: (1) Without therapy patients develop allergic symptoms upon exposure to environmental pollen, (2) with therapy patients do not develop symptoms upon exposure, and (3) patients do not develop allergic symptoms to the therapy itself. We defined scores for therapeutic success and identified ranges of parameters in which allergen immunotherapy is likely to be successful. Treg cells have a longer lifespan than Th2 cells, allowing accumulation over many years. In accordance, therapy with linear dose increases (rather than constant doses) reduced the risk of allergies to the therapy itself, and led to stronger accumulation of resistance to pollen exposure.

Original languageEnglish
Pages (from-to)23-42
Number of pages20
JournalJournal of Theoretical Biology
Volume425
DOIs
Publication statusPublished - Jul 21 2017

Fingerprint

Allergens
Immunotherapy
Immunologic Desensitization
immunotherapy
allergens
Pollen
Therapy
Allergies
T-cells
signs and symptoms (animals and humans)
therapeutics
pollen
Th2 Cells
T-lymphocytes
Regulatory T-Lymphocytes
Dose
Therapeutics
Mathematical models
hay fever
Life Span

All Science Journal Classification (ASJC) codes

  • Statistics and Probability
  • Modelling and Simulation
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Agricultural and Biological Sciences(all)
  • Applied Mathematics

Cite this

When is allergen immunotherapy effective? / Hara, Akane; Iwasa, Yoh.

In: Journal of Theoretical Biology, Vol. 425, 21.07.2017, p. 23-42.

Research output: Contribution to journalArticle

Hara, Akane ; Iwasa, Yoh. / When is allergen immunotherapy effective?. In: Journal of Theoretical Biology. 2017 ; Vol. 425. pp. 23-42.
@article{7158fae83a0647c1adf2dfa4bd96d532,
title = "When is allergen immunotherapy effective?",
abstract = "Allergen immunotherapy is used to treat allergic symptoms such as rhinitis and itchy eyes in Japanese patients with cedar pollen allergy (JCPA). Administration of small amounts of pollen over several years may suppress severe allergic symptoms when these patients are later exposed to large amounts of pollen in the environment. Herein, we developed a simple mathematical model to identify conditions in which allergen immunotherapy is effective. We considered the dynamics of type 2 T helper cells (Th2) and regulatory T cells (Treg), both of which differentiate from naive T cells. Therapy was considered successful under the following three conditions: (1) Without therapy patients develop allergic symptoms upon exposure to environmental pollen, (2) with therapy patients do not develop symptoms upon exposure, and (3) patients do not develop allergic symptoms to the therapy itself. We defined scores for therapeutic success and identified ranges of parameters in which allergen immunotherapy is likely to be successful. Treg cells have a longer lifespan than Th2 cells, allowing accumulation over many years. In accordance, therapy with linear dose increases (rather than constant doses) reduced the risk of allergies to the therapy itself, and led to stronger accumulation of resistance to pollen exposure.",
author = "Akane Hara and Yoh Iwasa",
year = "2017",
month = "7",
day = "21",
doi = "10.1016/j.jtbi.2017.04.030",
language = "English",
volume = "425",
pages = "23--42",
journal = "Journal of Theoretical Biology",
issn = "0022-5193",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - When is allergen immunotherapy effective?

AU - Hara, Akane

AU - Iwasa, Yoh

PY - 2017/7/21

Y1 - 2017/7/21

N2 - Allergen immunotherapy is used to treat allergic symptoms such as rhinitis and itchy eyes in Japanese patients with cedar pollen allergy (JCPA). Administration of small amounts of pollen over several years may suppress severe allergic symptoms when these patients are later exposed to large amounts of pollen in the environment. Herein, we developed a simple mathematical model to identify conditions in which allergen immunotherapy is effective. We considered the dynamics of type 2 T helper cells (Th2) and regulatory T cells (Treg), both of which differentiate from naive T cells. Therapy was considered successful under the following three conditions: (1) Without therapy patients develop allergic symptoms upon exposure to environmental pollen, (2) with therapy patients do not develop symptoms upon exposure, and (3) patients do not develop allergic symptoms to the therapy itself. We defined scores for therapeutic success and identified ranges of parameters in which allergen immunotherapy is likely to be successful. Treg cells have a longer lifespan than Th2 cells, allowing accumulation over many years. In accordance, therapy with linear dose increases (rather than constant doses) reduced the risk of allergies to the therapy itself, and led to stronger accumulation of resistance to pollen exposure.

AB - Allergen immunotherapy is used to treat allergic symptoms such as rhinitis and itchy eyes in Japanese patients with cedar pollen allergy (JCPA). Administration of small amounts of pollen over several years may suppress severe allergic symptoms when these patients are later exposed to large amounts of pollen in the environment. Herein, we developed a simple mathematical model to identify conditions in which allergen immunotherapy is effective. We considered the dynamics of type 2 T helper cells (Th2) and regulatory T cells (Treg), both of which differentiate from naive T cells. Therapy was considered successful under the following three conditions: (1) Without therapy patients develop allergic symptoms upon exposure to environmental pollen, (2) with therapy patients do not develop symptoms upon exposure, and (3) patients do not develop allergic symptoms to the therapy itself. We defined scores for therapeutic success and identified ranges of parameters in which allergen immunotherapy is likely to be successful. Treg cells have a longer lifespan than Th2 cells, allowing accumulation over many years. In accordance, therapy with linear dose increases (rather than constant doses) reduced the risk of allergies to the therapy itself, and led to stronger accumulation of resistance to pollen exposure.

UR - http://www.scopus.com/inward/record.url?scp=85019127050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019127050&partnerID=8YFLogxK

U2 - 10.1016/j.jtbi.2017.04.030

DO - 10.1016/j.jtbi.2017.04.030

M3 - Article

C2 - 28483565

AN - SCOPUS:85019127050

VL - 425

SP - 23

EP - 42

JO - Journal of Theoretical Biology

JF - Journal of Theoretical Biology

SN - 0022-5193

ER -